17 October 2018 - Submission for complicated urinary tract infections, bloodstream infections, and infections due to Enterobacteriaceae in adult patients with limited treatment options.

Achaogen today announced the submission of a marketing authorisation application to the EMA for plazomicin. 

The Company is seeking approval for the following indications:

• Complicated urinary tract infections, including pyelonephritis,
  
• Bloodstream infections due to certain Enterobacteriaceae and
  
• Infections due to Enterobacteriaceae in adult patients with limited treatment options
  

Read Achaogen press release